Diagnostic Accuracy of APRI, AAR, FIB-4, Fl, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis

A Systematic Review and Meta-Analysis

Han Deng, MS, Xingshun Qi, MD, and Xiaozhong Guo, MD, PhD

Abstract: Aspartate aminotransferase-to-platelet ratio (APRI), aspartate aminotransferase-to-alanine aminotransferase ratio (AAR), FIB-4, Fl, King, Lok, Forns, and FibroIndex scores may be simple and convenient noninvasive diagnostic tests, because they are based on the regular laboratory tests and demographic data. This study aimed to systematically evaluate their diagnostic accuracy for the prediction of varices in liver cirrhosis.

All relevant papers were searched via PubMed, EMBASE, CNKI, and Wanfang databases. The area under the summary receiver operating characteristic curve (AUSROC), sensitivity, specificity, positive and negative likelihood ratio (PLR and NLR), and diagnostic odds ratio (DOR) were calculated.

Overall, 12, 4, 5, 0, 0, 4, 3, and 1 paper was identified to explore the diagnostic accuracy of APRI, AAR, FIB-4, Fl, King, Lok, Forns, and FibroIndex scores, respectively. The AUSROCs of APRI, AAR, FIB-4, Lok, and Forns scores for the prediction of varices were 0.6774, 0.7275, 0.7755, 0.7885, and 0.7517, respectively; and those for the prediction of large varices were 0.7278, 0.7448, 0.7095, 0.7264, and 0.6530, respectively. The diagnostic threshold effects of FIB-4 and Forns scores for the prediction of varices were statistically significant. The sensitivities/specificities/PLRs/NLRs/DORs of APRI, AAR, Lok, and Forns scores for the prediction of varices were 0.60/0.67/1.77/0.58/3.13, 0.64/0.63/1.97/0.54/1.18, and 0.74/0.68/2.34/0.40/5.76, respectively. The sensitivities/specificities/PLRs/NLRs/DORs of APRI, AAR, FIB-4, Lok, and Forns scores for the prediction of large varices were 0.65/0.66/2.15/0.47/4.97, 0.68/0.58/2.07/0.54/3.93, 0.62/0.64/2.02/0.56/3.57, 0.78/0.63/2.09/0.37/5.55, and 0.65/0.61/1.62/0.59/2.75, respectively.

APRI, AAR, FIB-4, Lok, and Forns scores had low to moderate diagnostic accuracy in predicting the presence of varices in liver cirrhosis.

INTRODUCTION

Variceal bleeding is one of the most lethal portal hypertension-related complications in liver cirrhosis. Early diagnosis and screening of varices should be warranted to improve the prognosis of liver cirrhosis. Upper gastrointestinal endoscopy is the golden diagnostic method for varices. However, given the invasiveness and relatively high cost of endoscopy and poor patients’ adherence, noninvasive diagnostic methods have been developed dramatically in the last decades.

Recently, several systematic reviews and meta-analyses have confirmed the diagnostic performances of transient elastography (TE), spleen stiffness (SS), and platelet count to spleen diameter ratio (PSR). First, a meta-analysis of 18 studies by Shi et al found that the summary sensitivity, specificity, and area under curve (AUC) of TE for the prediction of esophageal varices (EV) were 0.87, 0.53, and 0.84, respectively; and those for the prediction of large EV were 0.86, 0.59, and 0.78, respectively. Second, a meta-analysis of 12 studies by Singh et al found that the summary sensitivity and specificity of SS for the prediction of EV were 0.78 and 0.76, respectively; and those for the prediction of large EV were 0.81 and 0.66, respectively. Third, a meta-analysis of 8 studies by Chawla et al found that the summary sensitivity and specificity of PSR for the prediction of EV were 0.89 and 0.74, respectively. Another meta-analysis of 20 studies by Ying et al also found that the summary sensitivity, specificity, and AUC of PSR for
As for FIB-4 score, the search items were as follows: 

((varices) AND liver cirrhosis) AND ((FIB-4 score) OR (((aspartate aminotransferase) AND alanine aminotransferase) AND platelets) AND age)).

As for FI score, the search items were as follows: 

((varices) AND liver cirrhosis) AND ((FI score) OR ((albumin) AND platelets)).

As for King score, the search items were as follows: 

((varices) AND liver cirrhosis) AND ((King score) OR (((aspartate aminotransferase) AND international normalized ratio) AND platelets) AND age)).

As for Lok score, the search items were as follows: 

((varices) AND liver cirrhosis) AND ((Lok) OR (((aspartate aminotransferase) AND alanine aminotransferase) AND platelets) AND international normalized ratio)).

As for Forns score, the search items were as follows: 

((varices) AND liver cirrhosis) AND ((Forns score) OR (((gamma-glutamyl transpeptidase) AND cholesterol) AND platelets) AND age)).

As for FibroIndex score, the search items were as follows: 

((varices) AND liver cirrhosis) AND ((FibroIndex) OR ((platelets) AND gamma globulin) AND aspartate aminotransferase)).

The last search was performed on April 26, 2015. Reference lists were also manually searched.

### Eligibility Criteria

#### Inclusion criteria were as follows:

1. All participants should be diagnosed with liver cirrhosis.
2. Reference tests (ie, upper gastrointestinal endoscopy) should be performed to evaluate the presence and/or grade of varices.
3. Alternative tests, such as APRI, AAR, FIB-4, FI, King, Lok, Forns, and/or FibroIndex scores, should be performed.
4. The diagnostic accuracy should be compared between reference and alternative tests.

#### Exclusion criteria were as follows:

1. Duplicates.
2. Commentaries and editorials.
3. Reviews.
4. Case reports.
5. Indexes or volumes.
6. Noncirrhotic patients.
7. Patients did not evaluate the presence of varices by upper gastrointestinal endoscopy.
8. Patients did not evaluate APRI, AAR, FIB-4, FI, King, Lok, Forns, or FibroIndex scores. 
9. Diagnostic accuracy data were lacking.

### Methods

This work is registered on PROSPERO database (registration number: CRD42015017519). Because this work is a systematic review of literatures, the ethical approval and patient consent are not necessary.

### Literature Search

All relevant papers were searched via the PubMed, EMBASE, CNKI, and Wanfang databases. PubMed and EMBASE were two major English-language databases, and CNKI and Wanfang databases were two major Chinese-language databases.

As for APRI score, the search items were as follows: 

((varices) AND liver cirrhosis) AND ((APRI) OR ((aspartate aminotransferase) AND alanine aminotransferase) AND platelets)).

As for AAR score, the search items were as follows: 

((varices) AND liver cirrhosis) AND ((AAR) OR ((aspartate aminotransferase) AND alanine aminotransferase)).

#### Formulas of Different Prediction Scores

| Score                  | Formulas                                                                 |
|------------------------|--------------------------------------------------------------------------|
| AST to platelets ratio index (APRI) | [(AST/ULN) × 100]/PLT                                                   |
| AST-to-ALT ratio (AAR) | AST/ALT                                                                  |
| FIB-4                  | (age × AST)/(PLT × ALT)−1/2                                              |
| FI                     | 8−0.01 × PLT−ALT                                                         |
| King                   | age × AST × INR × PLT−0.089 × PLT + 1.26 × AST × ALT + 5.27 × INR        |
| Forns                  | 7.811−3.131 × ln(PLT) + 0.781 × ln(GGT) + 3.467 × ln(age) − 0.14 × (cholesterol) |
| FibroIndex             | 1.738−0.064 × PLT + 0.005 × AST + 0.463 × gamma globulin                |

ALB = albumin, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BIL = bilirubin, FI = fibrosis index, FIB-4 = fibrosis 4 index, GGT = gamma glutamyl transpeptidase, HE = hepatic encephalopathy, INR = international normalized ratio, PLT = platelets count, ULN = upper limit of normal.
TABLE 2. Results of Meta-Analyses: An Overview

| Groups          | APRI for the Presence of Varices | APRI for the Presence of Large Varices | AAR for the Presence of Varices | AAR for the Presence of Large Varices | FIB-4 for the Presence of Varices | FIB-4 for the Presence of Large Varices | Lok for the Presence of Varices | Lok for the Presence of Large Varices | Forns for the Presence of Varices | Forns for the Presence of Large Varices |
|-----------------|----------------------------------|----------------------------------------|---------------------------------|---------------------------------------|-----------------------------------|----------------------------------------|-----------------------------------|-------------------------------------|-----------------------------------|-------------------------------------|
| Diagnostic threshold |                                  |                                        |                                 |                                       |                                   |                                        |                                   |                                     |                                   |                                     |
| Spearman correlation coefficient | 0.310                             | −0.381                                 | 0.400                           | −0.866                                | −0.900                            | 0.600                                  | 0.800                             | 0.400                               | 1.000                             | 0.500                               |
| P-value          | 0.354                             | 0.352                                 | 0.600                           | 0.333                                 | 0.037                             | 0.400                                  | 0.200                             | 0.600                               | 0.000                             | 0.667                               |
| AUSROC           |                                   |                                        |                                 |                                       |                                   |                                        |                                   |                                     |                                   |                                     |
| AUC (SE)         | 0.6774                            | 0.7278                                 | 0.7275                          | 0.7448                                | 0.7755                            | 0.7095                                  | 0.7885                           | 0.7264                               | 0.7517                            | 0.6530                               |
| (0.0258)         | (0.0569)                          | (0.0398)                               | (0.0396)                        | (0.0414)                              | (0.0416)                          | (0.0211)                                | (0.0581)                         | (0.0222)                            | (0.0295)                          |                                     |
| Q index (SE)     | 0.6351                            | 0.6752                                 | 0.6750                          | 0.6891                                | 0.7148                            | 0.6605                                  | 0.7259                           | 0.6741                               | 0.6948                            | 0.6160                               |
| (0.0203)         | (0.0462)                          | (0.0223)                               | (0.0326)                        | (0.0352)                              | (0.0333)                          | (0.0182)                                | (0.0471)                         | (0.0184)                            | (0.0229)                          |                                     |
| Sensitivity      |                                   |                                        |                                 |                                       |                                   |                                        |                                   |                                     |                                   |                                     |
| Pooled sensitivity (95% CI) | 0.60 (0.57–0.63)                    | 0.65 (0.60–0.70)                       | 0.64 (0.60–0.69)                  | 0.68 (0.60–0.76)                    | NA                               | 0.62 (0.55–0.68)                      | 0.74 (0.70–0.77)                  | 0.78 (0.71–0.83)                    | NA                               | 0.65 (0.58–0.72)                     |
| Heterogeneity    | 64.3%                             | 79.3%                                 | 27.6%                           | 0%                                    | NA                               | 72.4%                                  | 48.1%                            | 3.9%                                 | NA                               | 36.0%                               |
| I²; P-value      | 0.0018                            | 0.0000                                | 0.2466                          | 0.9909                                | NA                               | 0.0125                                 | 0.1227                           | 0.3732                               | NA                               | 0.2097                              |
| Specificity      |                                   |                                        |                                 |                                       |                                   |                                        |                                   |                                     |                                   |                                     |
| Pooled specificity (95% CI) | 0.67 (0.64–0.70)                    | 0.66 (0.63–0.69)                       | 0.63 (0.58–0.68)                  | 0.58 (0.54–0.62)                    | NA                               | 0.64 (0.61–0.68)                      | 0.68 (0.63–0.73)                  | 0.63 (0.59–0.67)                    | NA                               | 0.61 (0.57–0.64)                     |
| Heterogeneity    | 75.5%                             | 80.4%                                 | 92.7%                           | 89.4%                                 | NA                               | 89.5%                                  | 79.9%                            | 42.2%                                 | NA                               | 0%                                  |
| I²; P-value      | 0.0000                            | 0.0000                                | 0.0000                          | 0.0001                                | NA                               | 0.0000                                 | 0.0019                           | 0.1587                               | NA                               | 0.6025                              |
| PLR              |                                   |                                        |                                 |                                       |                                   |                                        |                                   |                                     |                                   |                                     |
| Pooled PLR (95% CI) | 1.77 (1.47–2.13)                    | 2.15 (1.55–2.98)                       | 1.97 (1.28–3.05)                  | 2.07 (1.28–3.36)                    | NA                               | 2.02 (1.50–2.72)                      | 2.34 (1.59–3.45)                  | 2.09 (1.77–2.46)                    | NA                               | 1.62 (1.40–1.88)                     |
| Heterogeneity    | 56.1%                             | 83.6%                                 | 83.4%                           | 77.8%                                 | NA                               | 59.9%                                  | 73.8%                            | 29%                                   | NA                               | 0%                                  |
| I²; P-value      | 0.0117                            | 0.0000                                | 0.0000                          | 0.0110                                | NA                               | 0.0578                                 | 0.0094                           | 0.2383                               | NA                               | 0.7926                              |
| NLR              |                                   |                                        |                                 |                                       |                                   |                                        |                                   |                                     |                                   |                                     |
| Pooled NLR (95% CI) | 0.58 (0.50–0.68)                    | 0.47 (0.32–0.68)                       | 0.54 (0.47–0.64)                  | 0.54 (0.42–0.70)                    | NA                               | 0.56 (0.43–0.72)                      | 0.40 (0.34–0.47)                  | 0.37 (0.29–0.48)                    | NA                               | 0.59 (0.49–0.73)                     |
| Heterogeneity    | 57.5%                             | 76.4%                                 | 0%                              | 0%                                    | NA                               | 45.9%                                  | 0%                                | 0%                                    | NA                               | 0%                                  |
| I²; P-value      | 0.0089                            | 0.0001                                | 0.4251                          | 0.4557                                | NA                               | 0.1362                                 | 0.4111                           | 0.5454                               | NA                               | 0.4993                              |
| DOR              |                                   |                                        |                                 |                                       |                                   |                                        |                                   |                                     |                                   |                                     |
| Pooled DOR (95% CI) | 3.13 (2.26–3.43)                    | 4.97 (2.43–10.16)                      | 4.18 (2.16–8.07)                  | 3.93 (1.87–8.28)                    | NA                               | 3.57 (2.34–5.44)                      | 5.76 (3.62–9.15)                  | 5.55 (3.85–8.00)                    | NA                               | 2.75 (1.96–3.87)                     |
| Heterogeneity    | 51.4%                             | 81.4%                                 | 60.4%                           | 53.5%                                 | NA                               | 30.1%                                  | 38.7%                            | 0%                                    | NA                               | 0%                                  |
| I²; P-value      | 0.0243                            | 0.0000                                | 0.0557                          | 0.1162                                | NA                               | 0.2314                                 | 0.1795                           | 0.4707                               | NA                               | 0.6149                              |

**AAR** = aspartate aminotransferase-to-alanine aminotransferase ratio, **APRI** = aspartate aminotransferase-to-platelet ratio, **AUC** = area under curve, **AUSROC** = area under the summary receiver operating characteristic curves, **CI** = confidence interval, **DORs** = diagnostic odds ratios, **NA** = not available, **NLR** = negative likelihood ratio, **PLR** = positive likelihood ratio, **SE** = standard error.
data were unclear, we contacted with the corresponding authors or submitted the letters to journal editors to validate the accuracy of data.20–22

Quality Assessment

Study quality was assessed by the QUADAS (Quality Assessment of Diagnostic Accuracy Studies) score, which consisted of 14 questions assessing the risk of bias, sources of variation, and reporting quality. According to the description of every study, each item was rated as “yes” (1 point), “no” (1 point), and “unclear” (0 point). If the QUADAS score was ≥10, the study was of relatively good quality. Otherwise, the study was of poor quality.

Data Analysis

The meta-analyses were performed by random-effects model in the Meta-DiSc software version 1.4. First, we extracted the TP, FP, FN, and TN values from original papers. If these data were missing, we recalculated these values based on the specificities and sensitivities reported.

Second, TP, FP, FN, and TN values were entered into the statistical software. The diagnostic threshold was analyzed by Spearman correlation coefficient and P-value. If there was no significant threshold effect, the diagnostic accuracy was evaluated by the area under the summary receiver operating characteristic curves (AUSROCs) with standard errors (SEs) and Q indexes with SEs, the summary positive and negative likelihood ratios (PLRs and NLRs) with 95% CIs, and the summary diagnostic odds ratios (DORs) with 95% CIs. If there was a significant threshold effect, the diagnostic accuracy was evaluated by only AUSROCs with SEs and Q indexes with SEs, rather than sensitivities, specificities, PLRs, NLRs, or DORs.

If the AUSROC was >0.9, the diagnostic accuracy would be high; if the AUSROC was 0.7 to 0.9, the diagnostic accuracy would be moderate; if the AUSROC was 0.5 to 0.7, the diagnostic accuracy would be low. A larger Q index suggested a higher diagnostic accuracy. PLR = sensitivity/[1-specificity]. A PLR was the probability of a patient with varices testing positive divided by the probability of a patient without varices testing positive. NLR = [1-sensitivity]/specificity. An NLR was the probability of a person with varices testing negative divided by the probability of a person without varices testing negative. A PLR > 5 and an NLR < 0.2 suggested a high diagnostic accuracy. DOR = PLR/NLR. A DOR was the ratio of the odds of positivity in a patient with varices relative to the odds of positivity in a patient without varices.

Third, the heterogeneity among studies was evaluated by Chi-square test and inconsistency index. P < 0.1 and/or I² > 50% was suggestive of considerable heterogeneity.

RESULTS

Literature Identification and Study Characteristics

APRI

Overall, 292 papers were identified. Among them, 12 papers were finally eligible for our study23–34 (Supplementary
The study characteristics are shown in Supplementary Table 1. They were performed in Austria (n = 1), Brazil (n = 2), China (n = 2), England (n = 1), France (n = 1), India (n = 1), Italy (n = 2), Japan (n = 1), and Romania (n = 1). Two and 10 of them were published in abstracts and full-texts, respectively. Both EV and GV were evaluated in one paper, and EV alone was evaluated in 11 papers. Prevalence of varices was 26% to 72.6%. Prevalence of large varices was 3.3% to 48.2%. QUADAS score was 8 to 12 (Supplementary Table 2). Seven and 5 of them were of relatively good and poor quality, respectively.

AAR
Overall, 241 papers were identified. Among them, 4 papers were finally eligible for our study (Supplementary Figure 2). The study characteristics are shown in Supplementary Table 3. They were performed in England (n = 1), France (n = 1), and Italy (n = 2). One and 3 of them were published in abstracts and full-texts, respectively. EV alone was evaluated in all of the 4 included papers. Prevalence of varices was 26% to 56.9%. Prevalence of large varices was 13.5% to 27.1%. QUADAS score was 7–12 (Supplementary Table 4). Four and 2 of them were of relatively good and poor quality, respectively.

FIB-4 Score
Overall, 17 papers were identified. Among them, 5 papers were finally eligible for our study (Supplementary Figure 3). The study characteristics are shown in Supplementary Table 5. They were performed in Egypt (n = 1), England (n = 1), Italy (n = 1), Japan (n = 1), and Romania (n = 1). One and 4 of them were published in abstracts and full-texts, respectively. EV alone was evaluated in all of the 5 included papers. Prevalence of varices was 26% to 76.9%. Prevalence of large varices was 13.5% to 49.2%. QUADAS score was 7–12 (Supplementary Table 6). Four and 1 of them were of relatively good and poor quality, respectively.

FI Score
Overall, 52 papers were identified. Among them, no papers were finally eligible for our study (Supplementary Figure 4).

King Score
Overall, 4 papers were identified. Among them, no papers were finally eligible for our study (Supplementary Figure 5).

Lok Score
Overall, 26 papers were identified. Among them, 4 papers were finally eligible for our study (Supplementary Figure 6). The study characteristics are shown in Supplementary Table 7. They were performed in Egypt (n = 1), Romania (n = 1), Italy (n = 1) and France (n = 1). All of them
were published in full-texts. EV alone was evaluated in all of the 4 included papers. Prevalence of varices was 35.7% to 76.9%. Prevalence of large varices was 18.6% to 49.2%. QUADAS score was 9 to 12 (Supplementary Table 8, http://links.lww.com/MD/A468). Three and 1 of them were of relatively good and poor quality, respectively.

Forns Score
Overall, 22 papers were identified. Among them, 3 papers were finally eligible for our study30,31,35 (Supplementary Figure 7, http://links.lww.com/MD/A468). The study characteristics are shown in Supplementary Table 9, http://links.lww.com/MD/A468. They were performed in Egypt (n = 1), Romania (n = 1), and Italy (n = 1). All of them were published in full-texts. EV alone was evaluated in all of the 3 included papers. Prevalence of varices was 56.9% to 76.9%. Prevalence of large varices was 19% to 49.2%. QUADAS score was 10 to 12 (Supplementary Table 10, http://links.lww.com/MD/A468). All of them were of relatively good quality.

FibroIndex
Overall, 15 papers were identified. Among them, only 1 paper was finally eligible for our study30 (Supplementary Figure 8, http://links.lww.com/MD/A468). The study characteristics are shown in Supplementary Table 11, http://links.lww.com/MD/A468. It was performed in Italy, and was published in
FIGURE 4. Summary sensitivities of APRI, AAR, FIB-4, Lok, and Forns scores for the prediction of large varices in liver cirrhosis. Panel A: APRI; panel B: AAR; panel C: FIB-4; panel D: Lok; panel E: Forns.
full-texts. EV alone was evaluated. Prevalence of varices was 56.9%. Prevalence of large varices was 19%. QUADAS score was 12 (Supplementary Table 12, http://links.lww.com/MD/A468).

Meta-Analyses

The results of meta-analyses are shown in Table 2. Notably, while FIB-4 and Forns scores were employed to predict the presence of varices, there were significant diagnostic threshold effects. Thus, the sensitivities, specificities, PLRs, NLRs, and DORs of FIB-4 and Forns scores for the prediction of varices in liver cirrhosis were not calculated.

SROC

The SROCs of APRI, AAR, FIB-4, Lok, and Forns scores for the prediction of varices are shown in Figure 1. Lok score had the largest summary AUC followed by FIB-4, Forns, AAR, and APRI scores.

The SROCs of APRI, AAR, FIB-4, Lok, and Forns scores for the prediction of large varices are shown in Figure 2. AAR score had the largest summary AUC followed by APRI, Lok, FIB-4, and Forns scores.

Sensitivity

The sensitivities of APRI, AAR, and Lok scores in the prediction of varices are shown in Figure 3. Lok score had the largest summary sensitivity followed by AAR and APRI scores. The lower limit of 95% CI of Lok score was larger than the upper limits of 95% CIs of AAR and APRI scores.

The sensitivities of APRI, AAR, FIB-4, Lok, and Forns scores in the prediction of large varices are shown in Figure 4.
FIGURE 6. Summary specificities of APRI, AAR, FIB-4, Lok, and Forns scores for the prediction of large varices in liver cirrhosis. Panel A: APRI; panel B: AAR; panel C: FIB-4; panel D: Lok; panel E: Forns.
Lok score had the largest summary sensitivity followed by AAR, Forns, APRI, and FIB-4 score, but their 95% CIs were overlapping.

Specificity

The specificities of APRI, AAR, and Lok scores in the prediction of varices are shown in Figure 5. Lok score had the largest summary sensitivity followed by APRI and AAR scores, but their 95% CIs were overlapping.

The specificities of APRI, AAR, FIB-4, Lok, and Forns scores in the prediction of large varices are shown in Figure 6. APRI score had the largest summary specificity followed by FIB-4, Lok, Forns, and AAR scores, but their 95% CIs were overlapping.

PLR

The PLRs of APRI, AAR, and Lok scores in the prediction of varices are shown in Supplementary Figure 9, http://links.lww.com/MD/A468. Lok score had the largest summary PLR followed by AAR and APRI scores, but their 95% CIs were overlapping.

The PLRs of APRI, AAR, FIB-4, Lok, and Forns scores in the prediction of large varices are shown in Supplementary Figure 10, http://links.lww.com/MD/A468. APRI score had the largest summary PLRs followed by Lok, AAR, FIB-4, and Forns score, but their 95% CIs were overlapping.

NLR

The NLRs of APRI, AAR, and Lok scores in the prediction of varices are shown in Supplementary Figure 11, http://links.lww.com/MD/A468. Lok score had the smallest summary NLR followed by AAR and APRI scores, but their 95% CIs were overlapping.

The NLRs of APRI, AAR, FIB-4, Lok, and Forns scores in the prediction of large varices are shown in Supplementary Figure 12, http://links.lww.com/MD/A468. Lok score had the smallest summary NLR followed by APRI, AAR, FIB-4, and Forns scores, but their 95% CIs were overlapping.

DOR

The DORs of APRI, AAR, and Lok scores in the prediction of varices are shown in Supplementary Figure 13, http://links.lww.com/MD/A468. Lok score had the largest summary DOR followed by AAR and APRI scores, but their 95% CIs were overlapping.

The DORs of APRI, AAR, FIB-4, Lok, and Forns scores in the prediction of large varices are shown in Supplementary Figure 14, http://links.lww.com/MD/A468. Lok score had the largest summary DOR followed by APRI, AAR, FIB-4, and Forns scores, but their 95% CIs were overlapping.

DISCUSSION

Currently, noninvasive diagnosis of varices is an important topic in the management of liver cirrhosis. However, our recent questionnaire survey suggested that noninvasive diagnostic tests of varices in liver cirrhosis were rarely used in clinical practices. This might be primarily because their reliability was questioned. We performed a systematic review to identify the papers regarding the role of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex scores for the prediction of varices in liver cirrhosis. Notably, to maximize the number of papers retrieved, a total of 4 databases were systematically searched, the reference lists were manually searched, and the publication language and date were not limited. Additionally, we contacted with the authors to validate the accuracy of relevant data. Generally, as we evaluated the diagnostic accuracy for the prediction of varices in liver cirrhosis, the meta-analyses demonstrated the following: the AUROCs ranged from 0.6774 to 0.7885, the summary sensitivities ranged from 0.60 to 0.74, the summary specificities ranged from 0.63 to 0.68, the summary PLRs ranged from 1.77 to 2.34, the summary NLRs ranged from 0.40 to 0.58, and the summary DORs ranged from 3.13 to 5.76. As we evaluated the diagnostic accuracy for the prediction of large varices, the meta-analysis demonstrated the following: the AUROCs ranged from 0.653 to 0.7448, the summary sensitivities ranged from 0.62 to 0.78, the summary specificities ranged from 0.58 to 0.66, the summary PLRs ranged from 1.62 to 2.15, the summary NLRs ranged from 0.37 to 0.59, and the summary DORs ranged from 2.75 to 5.55. These findings suggested low to moderate diagnostic accuracy of APRI, AAR, FIB-4, Lok, and Forns scores in predicting the presence of varices or large varices in liver cirrhosis. According to several previous meta-analyses, we had to acknowledge that APRI, AAR, FIB-4, Lok, and Forns scores might be inferior to TE, SS, and PSR for the prediction of varices. Thus, their clinical utility might be compromised.

APRI, AAR, FIB-4, Lok, and Forns scores were firstly introduced to evaluate the presence and severity of liver fibrosis in patients with chronic viral hepatitis. Their components include age, alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol, gamma glutamyl transpeptidase (GGT), international normalized ratio (INR), and platelets (PLT). In 2002, Forns et al identified age, AST, ALT, and PLT as independent predictors of fibrosis in patients with chronic hepatitis C. Forns score = ln(GGT) + ln(ALT)/2. In 2003, Wai et al constructed the APRI score and validated it in patients with chronic hepatitis C. APRI score = ln(AST/upper limit of normal range) × 100/PLT. At the same year, Giannini et al also evaluated the correlation of AAR score with the histological stage and prognosis of hepatitis C virus-related liver diseases.

Since their original development, numerous studies have confirmed the values of APRI, AAR, FIB-4, Lok, and Forns scores in the diagnosis of liver fibrosis and cirrhosis. Recently, 2 meta-analyses by Jin et al and Shaheen and Myers explored the diagnostic accuracy of APRI for the prediction of hepatitis B and C-related fibrosis respectively. More recently, a meta-analysis by Xiao et al suggested that APRI and FIB-4 should have moderate sensitivity and specificity of detecting the presence of liver fibrosis. The mean AUROCs of APRI and FIB-4 for the prediction of significant fibrosis were 0.72 and 0.76, respectively. Similarly, our meta-analysis also demonstrated that the summary AUROCs of APRI, AAR, FIB-4, Lok, and Forns scores for the prediction of varices were 0.6774, 0.7275, 0.7755, 0.7885, and 0.7517, respectively; and those for the prediction of large varices were 0.7278, 0.7448, 0.7095, 0.7264, and 0.6530, respectively. The diagnostic accuracy appeared to be similar.
among them, because their 95% CIs of sensitivities, specificities, PLRs, NLRs, and DORs were mostly overlapping.

However, we had to acknowledge that their sensitivities and specificities were relatively low (about 70%). Thus, the reliability of these noninvasive diagnostic methods of varices in liver cirrhosis should be questioned.

Our systematic review and meta-analysis had several limitations. First, although 8 scores were systematically reviewed in our study, we did not identify any relevant papers to explore the role of FI or King score for the prediction of varices. FJ score was based on platelets and albumin. Additionally, the diagnostic accuracy of FibroIndex was evaluated in only one paper. King score consisted of age, AST, INR, and platelets. All of them played important roles in diagnosing the liver fibrosis. However, their associations with varices in liver cirrhosis needed to be explored. Second, the diagnostic threshold effect was statistically significant in the meta-analyses regarding the role of FIB-4 and Forns scores in predicting the presence of varices in liver cirrhosis. Thus, their sensitivities, specificities, PLRs, NLRs, and DORs were not combined. Third, the heterogeneity among studies was statistically significant in most of meta-analyses. Certainly, we employed random-effects models to perform all meta-analyses.

In conclusion, based on a systematic review and meta-analysis, APRI, AAR, FIB-4, Lok, and Forns scores had low to moderate diagnostic accuracy in predicting the presence of varices and large varices in liver cirrhosis. Thus, they might not be adequate to replace the use of upper gastrointestinal endoscopy. Further studies should be warranted to confirm these findings and to explore the potential correlations of FI, King, and FibroIndex scores with the presence of varices in liver cirrhosis.

REFERENCES

1. Biecker E. Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol. 2013;19:5035–5050.
2. Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015.
3. Turon F, Casu S, Hernandez-Gea V, et al. Variceal and other portal hypertension related bleeding. Best Pract Res Clin Gastroenterol. 2013;27:649–664.
4. Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol. 2014;20:4300–4315.
5. Stefanescu H, Procopet B. Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond. World J Gastroenterol. 2014;20:16811–16819.
6. Shi KQ, Fan YC, Pan ZZ, et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int. 2013;33:62–71.
7. Singh S, Eaton JE, Murad MH, et al. Accuracy of spleen stiffness measurement in detection of esophageal varices in patients with chronic liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:935.e4–945.e4.
8. Chawla S, Katz A, Attar BM, et al. Platelet count/spleen diameter ratio to predict the presence of esophageal varices in patients with cirrhosis: a systematic review. Eur J Gastroenterol Hepatol. 2012;24:431–436.
9. Ying L, Lin X, Xie ZL, et al. Performance of platelet count/spleen diameter ratio for diagnosis of esophageal varices in cirrhosis: a meta-analysis. Dig Dis Sci. 2012;57:1672–1681.
10. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
11. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163:218–224.
12. Sterling RK, Lissen E, Clumeneck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325.
13. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–36.
14. Ohta T, Sakaguchi K, Fujwara A, et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama. 2006;60:77–84.
15. Cross TJ, Rizzi P, Berry PA, et al. King’s Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21:730–738.
16. Cross TJ, Calvaruso V, Maimone S, et al. Prospective comparison of Fibroscan, King’s score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat. 2010;17:546–554.
17. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005;42:282–292.
18. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36 (4 Pt 1):986–992.
19. Koda M, Matunaga Y, Kawakami M, et al. Fibro Index a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007;45:297–306.
20. Morishita N, Hiramatsu N, Ozé T, et al. Erratum to: Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis. J Gastroenterol. 2015;50:705.
21. Deng H, Qi X, Wang Y, et al. Directions of odds ratios might be inappropriate in the paper by Tafarel et al. Eur J Gastroenterol Hepatol. 2015;27:475.
22. Deng H, Qi X, Wang Y, et al. Diagnostic accuracy of data on aspartate aminotransferase to platelets index might be false in the paper by Tafarel et al. Eur J Gastroenterol Hepatol. 2015;27:981.
23. Calvaruso V, Bronte F, Conte E, et al. Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. J Viral Hepat. 2013;20:867–874.
24. Castera L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59–68.
25. Feng J, Pan CW, Huang CJ. The diagnostic value of APRI and AAR for the esophageal varices in patient with cirrhosis (Article in Chinese). Mod Diag Interv. 2013;18:129–131.
26. Morishita N, Hiramatsu N, Oze T, et al. Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis. J Gastroenterol. 2014;49:1175–1182.
27. Pai CG, Kanhangad MP, Suvarna D, et al. Non-invasive markers for predicting large oesophageal varices in liver cirrhosis. *Gastrointest Endosc.* 2012;75:AB469.

28. Reed E, Stanley A, Forrest E, et al. Transient elastography as a predictor of oesophageal varices, a comparison with other non-invasive markers. *Gut.* 2011;60:A244–A245.

29. Salzl P, Reiberger T, Ferlitsch M, et al. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index. *Ultraschall Med.* 2014;35:528–533 doi: 10.1055/s-0034-1366506. Epub 2014 May 28.

30. Sebastiani G, Tempesta D, Fattovich G, et al. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: results of a multicentric, large-scale study. *J Hepatol.* 2010;53:630–638.

31. Stefanescu H, Grigorescu M, Lupșor M, et al. A new and simple algorithm for the noninvasive assessment of esophageal varices in cirrhotic patients using serum fibrosis markers and transient elastography. *J Gastrointest Liver Dis.* 2011;20:57–64.

32. Tafarel JR, Tolentino LH, Correa LM, et al. Prediction of esophageal varices in hepatic cirrhosis by noninvasive markers. *Eur J Gastroenterol Hepatol.* 2011;23:754–758.

33. Wang JH, Chuah SK, Lu SN, et al. Transient elastography and simple blood markers in the diagnosis of esophageal varices for compensated patients with hepatitis B virus-related cirrhosis. *J Gastroenterol Hepatol.* 2012;27:1213–1218.

34. Zambam de Mattos A, Alves de Mattos A, Daros LF, et al. Aspartate aminotransferase-to-platelet ratio index (APRI) for the non-invasive prediction of esophageal varices. *Ann Hepatol.* 2013;12:810–814.

35. Hassan EM, Omran DA, El Beshlawey ML, et al. Can transient elastography, Fib-4, Forns Index, and Lok Score predict esophageal varices in HCV-related cirrhotic patients? *Gastroenterol Hepatol.* 2014;37:58–65.

36. Qi X, Guo X, Li H, et al. Knowledge about non-invasive diagnostic tests for varices in liver cirrhosis: a questionnaire survey to the Gastroenterology Branch of the Liaoning Medical Association, China. *Gastroenterol Rep (Oxf).* 2015.

37. Jin W, Lin Z, Xin Y, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. *BMC Gastroenterol.* 2012;12:14.

38. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology.* 2007;46:912–921.

39. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. *Hepatology.* 2015;61:292–302.